Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
September 28, 2026 6:09 AM
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Overweight rating, PT $8.00.The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
